Orange, California 92868

  • Prostate Cancer

Purpose:

The purpose of this research study is to evaluate the response of Taxotere (docetaxel/prednisone) plus Sunitinib in subjects with newly diagnosed prostate cancer stage D1 or D2 which means cancer that has spread to lymph nodes near or far from the prostate, or to other parts of the body, such as the bladder, rectum, bones, liver, or lungs, with either measurable or non-measurable disease. This is an advanced stage of prostate cancer which considered incurable with standard therapy. Taxotere is a chemotherapy drug that is approved by the FDA for treatment of certain types of breast and lung cancer. It has also been studied extensively and approved for subjects with prostate cancer that has spread to other parts of the body. In these studies, Taxotere® has been shown to shrink tumors in some subjects with prostate cancer. Taxotere® is being tested in this study to see if it can help reduce the chance of prostate cancer returning after surgery. It has not been approved for use in the kind of cancer that subjects in this study have, so the use of Taxotere® in this study is considered experimental. Sutent (sunitinib) is designed to block tumor cell growth in several ways. Sutent targets several enzymes on blood vessel cells and tumor cells. Several of these targets are thought to be involved in angiogenesis (making of blood vessels). Sutent was approved by the FDA for the treatment of advanced renal cell cancer. Sutent has also been approved by the FDA for the treatment of certain types of intestinal cancerous growths (gastrointestinal stromal tumors) after these tumors have grown in size or the subject was not able to take a drug called imatinib mesylate (Gleevec®). Subjects will first receive Sunitinib orally once daily at a 37.5 mg starting dose for two weeks to assure tolerability. Dose reductions of Sunitinib will be required in the case of clinically relevant grade 3 or 4 toxic effects (to 25 mg/day then 12.5 mg/day given criteria for withdrawal from study drug are not met). Then, subjects will receive docetaxel (75 mg/m2) every 21 days plus prednisone 5mg twice a day and a tolerant dose of Sunitinib derived from above for a total of 6 cycles. After docetaxel/prednisone/ Sunitinib, a tolerant dose of Sunitinib in 6-week cycles with 4 weeks on and 2 weeks off treatment will be continued for an additional 6 months.


Criteria:

Inclusion Criteria 1. Subjects must have a histological diagnosis of adenocarcinoma of the prostate which is measurable or evaluable Stage D1 or D2 2. Age > 18 3. Subjects must have metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy by one or more of the following (despite androgen deprivation and antiandorgen withdrawal when applicable) check all that apply. - Progression of bidimensionally measurable disease (see section 10.1a) assessed within 28 days prior to registration. - Progression of evaluable but not measurable disease (i.e., bone scan ) assessed with 42 days prior to registration - Rising PSA - Rising PSA is defined as at least two consecutive rises in PSA to be documented over a reference value ( measure 1). The first rising PSA ( measure 2) must be at taken at least 7 days after the reference value. A third confirmatory PSA measure is required (2nd beyond the reference level) to be greater than the second measure, and it must be obtained at least 7 days after the 2nd measure. If this is not the case, a fourth PSA is required to be taken and be greater than the second measure. The Subject must have a PSA≥ 5 ng/ml in addition to increasing PSA to be eligible. 4. Subjects may have received prior surgery. However, at least 21 days must have elapsed since completion of surgery and Subject must have recovered from all side effects. 5. Subjects must have stopped biophosphnates at least 28 days prior to enrollment. Subjects should not be planning to receive concomitant bisphosphonates. 6. Subjects must have adequate hepatic function as defined by: - a serum bilirubin ≤1.5 x the institutional upper limit of normal (IULN), - SGOT or SGPT ≤2.5 x the institutional upper limit of normal obtained within 14 days prior to start of therapy 7. Subjects must have a pre-study PSA within 28 days prior to start of therapy 8. Subject may have measurable metastatic diseases by a CT scan of the abdomen and pelvis within 28 days and by a bone scan within 42 days prior to start of therapy. The Subject is required to have an elevated PSA ≥ 2 that has failed to respond to hormone therapy. 9. Subjects must have been surgically or medically castrated. If method of castration is LHRH agonist (leuprolide or goserelin), then the Subject should be willing to continue the use of LHRN agonists. Castration using LHRH agonist should not be interrupted and subjects who have stopped treatment should be willing to restart. 10. Subjects must not take vitamins, herbs, or micronutrient supplement within 28 days prior to start of therapy. 11. Prior radiation therapy (to less than 30% of the bone marrow only) is allowed. This includes prior use of samarium, but subjects can not have received prior strontium. At least 28 days must have elapsed since the completion of radiation therapy and the Subject must have recovered from side effects. Soft tissue disease which has been radiated in the prior 2 months is not assessable as measurable disease. 12. Subjects with a history of myocardial infarction are not eligible. Subjects must have a baseline EKG to rule out underlying cardiac disease within 42 days prior to registration. Subjects with a history of cardiac disease, specifically CHF are ineligible unless their disease is well-controlled. Subjects with history of CVA or atrial fibrillation are ineligible. 13. Subjects with a history of brain metastases or who currently have treated or untreated brain metastases are not eligible. Subjects with clinical evidence of brain metastases must have a brain CT or MRI negative for metastatic disease within 56 days prior to registration. *Liver function tests should be evaluated prior to each treatment. 14. Subjects must have an ECOG performance status 0-2. 15. Subjects must have an adequate renal function as defined by: •a serum creatinine ≤1.5 x the institutional upper limit of normal obtained within 14 days prior to start of therapy and a urine protein: creatinine (UPC) ratio of ≤ 1.0. 16. Subjects must have the following hematological criteria (minimal values): - Absolute neutrophil count > 1,500/mm³ - Hemoglobin of > 8.0gm/dL, - White blood cell count >2500, - Platelets > 100,000/mm³ 17. Subjects must be able to take oral medications EXCLUSION 1. Subjects must not have received chemotherapy, biologic therapy or any other investigational drug for any reason within 28 days prior to start of therapy and must have recovered from toxicities of prior therapy to grade 1 or less with the exception of alopecia. 2. Subjects may not have ongoing problems with bowel obstruction or short bowel syndrome characterized by grade 2 or greater diarrhea or malabsorptive disorders. 3. Men of child bearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter. 4. Subjects with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80 will be excluded 5. Subjects should not have psychological, familial, sociological, or geographical conditions that do not permit medical follow-up or compliance with the study protocol. 6. Except for cancer-related abnormalities, subjects should not have unstable or preexisting major medical conditions. 7. Subjects should not have any medical life-threatening complications of their malignancies 8. Subjects should not have a known severe and/or uncontrolled concurrent medical disease (e.g., uncontrolled diabetes, uncontrolled chronic renal or liver disease, active uncontrolled infection, or HIV). 9. Subjects should not have current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study. 10. Baseline blood pressure of < or equal to 150/100 mmHg. Subjects with a blood pressure reading above this level should be initiated on anti-hypertensive therapy and may be considered for protocol treatment when their blood pressure is adequately controlled. 11. Subjects with New York Heart Association (NYHA) Grade II or greater congestive heart failure are not eligible. 12. Subjects with clinically significant peripheral vascular disease are not eligible. 13. Subjects with evidence of bleeding diathesis or coagulopathy are not eligible. 14. Subjects with central nervous system or brain metastases are not eligible. 15. Subjects who had major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study are not eligible. 16. Subjects with minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to Day 0 are not eligible. 17. Subjects with history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess are not eligible. 18. Subjects with serious, non-healing wound, ulcer, or bone fracture are not eligible. 19. Subjects who are diagnosed of any other malignancy except non-melanomatous skin cancer in the past 5 years are not eligible. 20. Subjects receiving anticoagulation therapy (e.g. Coumadin) prior to registration are not eligible. Subjects are permitted to have prior Coumadin for prophylaxis against agents that might produce blood clots. Subjects with Aspirin are acceptable. 21. Subjects with active thrombophlebitis or hypercoagulability are not eligible. Subjects with known history of pulmonary embolus are not eligible. 22. Subjects must have completed the baseline quality of life (QOL) measures prior to registration: the EORTC QLQ-C30 plus the prostate cancer module; the McGill Pain Questionnaire; the Pain Medication Log. The nurse or Clinical Research Associate must complete the QOL cover sheet for the baseline assessment prior to registration. Subject must be willing to complete other questionnaires while on study or they are not eligible. 23. All Subjects must be informed and must sign and give written informed consent in accordance with institutional and federal guidelines. Subjects who are unable to comply with study and/or follow-up procedures are not eligible.


NCT ID:

NCT00879619


Primary Contact:

Principal Investigator
John P FRUEHAUF, MD
Chao Family Comprehensive Cancer Center

Chao Family Comprehensive Cancer Center University of California, Irvine
Phone: 1-877-UC-STUDY
Email: ucstudy@uci.edu


Backup Contact:

N/A


Location Contact:

Orange, California 92868
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: September 28, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.